Avid Technology, Inc. stock price

Avid Technology, Inc. latest news:


  • 08/14/2017 15:26:44

    Tepper's Appaloosa dumps Snap Inc., stake, loads up on tech, health care

    David Tepper's hedge fund Appaloosa Management unloaded its position in Snapchat-parent Snap Inc., and disclosed increases in the tech and health-care sectors at the end of the second quarter. As of June 30, Tepper's fund showed that his fund dumped 100,000 shares of of Snap Inc. , which has lost more than a third of its value since it debuted as a public entity in early March. Tepper had been one of a number of prominent investors who had vocally expressed support of the social-messaging company. On Monday, Snap's shares were among the most active, gaining about 6.5% to start the week. Elsewhere, Appaloosa showed new positions in the PowerShares QQQ Trust Series 1 , which mimics the technology laden Nasdaq-100 , purchasing 1.8 million shares of the so-called QQQs, valued at $249 million, representing about 3.7% of his overall portfolio, according to data from research provider Whalewisdom.com. The fund also more than doubled its Apple Inc. position to 625,000 shares worth about $90 million and those of Altaba Inc. , which he boosted to 5.1 million shares valued at $280 million. Appaloosa showed a fresh stake in Alibaba Group Holding Limited , scooping up 3.6 million shares worth $520 million. Tepper's investment vehicle added a new position in exchange-traded IBB , a prominent ETF tracking the biotech sector, and SPDR S&P Biotech ETF , which closely mimics the S&P 500's health-care sector. Tepper's firm bought 235,000 shares of IBB worth about $73 million and 330,000 shares of XBI valued at $34 million, as of the end of June. In other sales, Tepper & Co. unloaded all of its position in Teva Pharmaceutical Industries , Energy Transfer Partners L.P. and Pfizer Inc. among others. Related: Active-managers have a new favorite toolMarket Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/14/2017 15:14:19

    Tepper's Appaloosa dumps Snap Inc. stake, loads up on tech, health care

    David Tepper's hedge fund Appaloosa Management unloaded its position in Snapchat-parent Snap Inc., and disclosed increases in the tech and health-care sectors at the end of the second quarter. As of June 30, Tepper's fund showed that his fund dumped 100,000 shares of of Snap Inc. , which has lost more than a third of its value since it debuted as a public entity in early March. Tepper had been one of a number of prominent investors who had vocally expressed support of the social-messaging company. On Monday, Snap's shares were among the most active, gaining about 6.5% to start the week. Elsewhere, Appaloosa showed new positions in the PowerShares QQQ Trust Series 1 , which mimics the technology laden Nasdaq-100 , purchasing 1.8 million shares of the so-called QQQs, valued at $249 million, representing about 3.7% of his overall portfolio, according to data from research provider Whalewisdom.com. The fund also more than doubled its Apple Inc. position to 625,000 shares worth about $90 million and those of Altaba Inc. , which he boosted to 5.1 million shares valued at $280 million. Appaloosa showed a fresh stake in Alibaba Group Holding Limited , scooping up 3.6 million shares worth $520 million. Tepper's investment vehicle added a new position in exchange-traded IBB , a prominent ETF tracking the biotech sector, and SPDR S&P Biotech ETF , which closely mimics the S&P 500's health-care sector. Tepper's firm bought 235,000 shares of IBB worth about $73 million and 330,000 shares of XBI valued at $34 million, as of the end of June. In other sales, Tepper & Co. unloaded all of its position in Teva Pharmaceutical Industries , Energy Transfer Partners L.P. and Pfizer Inc. among others.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/14/2017 15:02:36

    David Einhorn's Greenlight Capital bulks up tech holdings

    David Einhorn's Greenlight Capital bulked up its stakes in technology companies in the second quarter, boosting its holding in Micron Technology Inc. and adding Hewlett Packard Enterprise Co. to its portfolio, according to a 13F regulatory filing submitted Monday. The hedge fund raised its stake in Micron to 2.6 million shares at the end of June from 1.6 million shares in March and bought 4.5 million shares of Hewlett Packard Enterprise. It also purchased 4.3 million shares in Altaba Inc. , a company that was formed after Yahoo's internet business was bought by Verizon Communications Inc. , but trimmed its stake in Apple Inc. to 3.93 million shares in the second quarter from 3.98 million shares in the first quarter. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 08/03/2017 15:21:56

    BRIEF-Avid Technology reports Q2 loss per share $0.31

    * Avid Technology announces Q2 2017 results and issues q3 2017 guidance

  • 07/19/2017 11:28:53

    AEterna Zentaris's stock more than doubles on heavy volume after favorable FDA ruling

    Shares of AEterna Zentaris Inc. more than doubled on heavy volume in afternoon trade Wednesday, after the biotechnology company received a favorable ruling by regulators regarding its treatment for growth hormone deficiency in adults, Macrilen. Volume exploded to 38.9 million shares in recent trade, compared with the full-day average of about 260,000 shares. The company said late Tuesday that the Food and Drug Administration accepted the new drug application (NDA) seeking approval of Macrilen as a "complete response." The FDA granted a Prescription Drug User Fee Act (PDUFA) date of Dec. 30. "We remain confident that the FDA will approve our NDA and, therefore, we are moving forward with our preparations to launch the product in the first quarter of 2018," said Chief Executive David Dodd. The stock has still lost 30% year to date, while the iShares Nasdaq Biotechnology ETF has climbed 20% and the S&P 500 has gained 10%. The FDA had issued a "complete response letter" (CRL) on Nov. 5, 2014 saying it couldn't approve the NDA in its present form because the clinical trial didn't by itself support the indication. The stock closed at a split-adjusted $129.00 the day before the CRL was announced.Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

  • 07/18/2017 14:33:08

    Harley-Davidson and Goldman Sachs fall but Netflix leaps

    Harley-Davidson and Goldman Sachs Group stumble while Netflix and Puma Biotechnology climb

  • More trends:

    Avinger, Inc.AVGR | Avis Budget Group, Inc.CAR | Aware, Inc.AWRE | Axcelis Technologies, Inc.ACLS | Axion Power International, Inc.AXPW | Axion Power International, Inc.AXPWW | AxoGen, Inc.AXGN | AXT IncAXTI | B Communications Ltd.BCOM | B. Riley Financial, Inc.RILY |